Tactile Systems Technology, Inc. ( TCMD) Stock. Should you Buy or Sell? $ 8.61
-0.21 (-2.50 %)
Tactile Systems Technology, Inc. AnalysisUpdated on 10-09-2022
|Volume Avg.||$379.99 thousand|
|Market Cap||$173.34 M|
|52 Week Range||$6.28 - $46.41|
Tactile Systems Technology, Inc. opened the day at $8.61 which is -2.50 % on yesterday's close. Tactile Systems Technology, Inc. has a 52 week high of $46.41 and 52 week low of $6.28, which is a difference of $40.13. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $173.34 M and total net profit is $208057000 which means the company is trading at 0.83 times profit to market capitalization. Theoretically, if you were to buy Tactile Systems Technology, Inc. for $173.34 M, it would take 15 years to get your money back. Tactile Systems Technology, Inc. are in the Medical Devices space which will have a sweet spot and industry standard for net profit multiples.
Tactile Systems Technology, Inc. Stock Forecast - Is Tactile Systems Technology, Inc. a Buy or Sell?
|DCF Score||Strong Buy|
|PE Score||Strong Sell|
|PB Score||Strong Buy|
Growth and Value
|Net Profit Margin||-0.140|
Valuing Tactile Systems Technology, Inc.
|Price Book Value Ratio||1.511||Price To Book Ratio||1.511|
|Price To Sales Ratio||0.777||Price Earnings Ratio||-5.551|
How liquid is Tactile Systems Technology, Inc.
|Debt Ratio||0.519||Debt Equity Ratio||1.079|
|Long Term Debt To Capitalization||0.378||Total Debt To Capitalization||0.396|
Latest news about Tactile Systems Technology, Inc.
Tactile Systems Technology, Inc. (NASDAQ:TCMD ) Q2 2022 Earnings Conference Call August 1, 2022 5:00 PM ET Company Participants Dan Reuvers - President and CEO Brent Moen - CFO Conference Call Participants Ryan Zimmerman - BTIG Simran Kaur - Piper Sandler Margaret Kaczor - William Blair Suraj Kalia - Oppenheimer & Company Operator Welcome ladies and gentlemen to the Second Quarter of Fiscal Year 2022 Earnings Conference Call for Tactile Medical. At this time, all participants have been placed in a listen-only mode.
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 12.50% and 4.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced that second quarter of fiscal year 2022 financial results will be released after the market closes on Monday, August 1st.
Millennium Management's Israel Englander is in focus after the billionaire's fund purchased several stocks this month. The post Billionaire Israel Englander Is Betting Big on These 5 Stocks appeared first on InvestorPlace.
Tactile Systems Technology, Inc. (NASDAQ:TCMD ) Q1 2022 Earnings Conference Call May 2, 2022 5:00 PM ET Company Participants Dan Reuvers - President and CEO Brent Moen - CFO Conference Call Participants Ryan Zimmerman - BTIG Adam Mandel - Piper Sandler Suraj Kalia - Oppenheimer Maggie Boeye - William Blair Operator Welcome ladies and gentlemen to the First Quarter of Fiscal Year 2022 Earnings Conference call for Tactile Medical. At this time, all participants have been placed in a listen-only mode.
About Tactile Systems Technology, Inc.
Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.